Jazz Pharmaceuticals announced its third quarter 2026 financial results, highlighting record quarterly revenues of $1.2 billion and raising its full-year 2026 total revenue guidance to a range of $4.775 billion to $4.85 billion. The company reported a GAAP net loss of $483.4 million for the quarter, primarily driven by a $754 million acquired in-process research and development expense related to the Actio Biosciences acquisition. Shareholders saw solid commercial execution, including growth in key product sales like Xywav and the recent launch of Ziihera.
Total revenues reached $1.24 billion in 3Q26, representing a 10% increase year-over-year.
GAAP net loss was $483.4 million in 3Q26, impacted by a $754 million acquired IPR&D charge for the Actio acquisition.
Full-year 2026 total revenue guidance was raised to $4.775 billion to $4.85 billion.
Xywav net product sales grew 12% year-over-year to $483 million in 3Q26.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Jazz Pharmaceuticals's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$4.27B
+4.9%
$-5.84
-167.5%
-8.3%
FY2024
$4.07B
+6.1%
$8.65
+41.8%
13.8%
FY2023
$3.83B
+4.8%
$6.10
—
10.8%
FY2022
$3.66B
+18.3%
$-3.58
—
-6.1%
FY2021
$3.09B
+30.9%
$-5.52
-230.8%
-10.7%
Frequently asked questions
When is Jazz Pharmaceuticals's next earnings date?
Jazz Pharmaceuticals has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Jazz Pharmaceuticals earn last quarter?
For the quarter ended Sep 2026, Jazz Pharmaceuticals reported diluted EPS of $-7.48 (-283.3% year over year) on revenue of $1.24B (+10.4%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.